SmithKline
Executive Summary
Halts development of AIDS drug, soluble T4, manufactured by Invitron, due to production scale-up problems. SmithKline said it will pursue second generation products "which work by the same mechanism but which can be produced in substantial quantities." Development of soluble T4, also known as CD4, provided 73% of Invitron's revenues in the first 9 months of 1989.